Network members
You are here
Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome.
Title | Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Carlton EF, Ice E, Barbaro RP, Kampuis L, Moss M, Angus DC, Banner-Goodspeed VM, Ginde AA, Gong MN, Grissom CK, Hou PC, Huang DT, Hough CTerri Lee, Talmor DS, B Thompson T, Yealy DM, Couper MP, Iwashyna TJ |
Corporate Authors | NHLBI Prevention and Early Treatment of Acute Lung Injury(PETAL) Network |
Journal | J Crit Care |
Volume | 64 |
Pagination | 160-164 |
Date Published | 2021 08 |
ISSN | 1557-8615 |
Keywords | Clinical Trials as Topic, Humans, Mental Recall, Patient Discharge, Respiratory Distress Syndrome, Survivors |
Abstract | PURPOSE: To measure the rate of recall of study participation and study attrition in survivors of acute respiratory distress syndrome(ARDS). MATERIALS/METHODS: In this ancillary study of the Re-evaluation of Systemic Early neuromuscular blockade(ROSE) trial, we measured the rate of study participation recall 3 months following discharge and subsequent study attrition at 6 months. We compared patient and hospital characteristics, and long-term outcomes by recall. As surrogate decision-makers provided initial consent, we measured the rate of patient reconsent and its association with study recall. RESULTS: Of 487 patients evaluated, recall status was determined in 386(82.7%). Among these, 287(74.4%) patients recalled participation in the ROSE trial, while 99(25.6%) did not. There was no significant difference in 6-month attrition among patients who recalled study participation (9.1%) and those who did not (12.1%) (p = 0.38). Patient characteristics were similar between groups, except SOFA scores, ventilator-free days, and length of stay. 330(68%) were reconsented. Compared to those not reconsented, significantly more patients who were reconsented recalled study participation(78% vs. 66%;p = 0.01). CONCLUSIONS: One in 4 ARDS survivors do not recall their participation in a clinical trial during hospitalization 3 months following hospital discharge, which did not influence 6-month attrition. However, more patients recall study participation if reconsent is obtained. |
DOI | 10.1016/j.jcrc.2021.04.006 |
Alternate Journal | J Crit Care |
PubMed ID | 33906105 |
PubMed Central ID | PMC8222163 |
Grant List | K12 HL138039 / HL / NHLBI NIH HHS / United States R01 HL153519 / HL / NHLBI NIH HHS / United States U01 HL123008 / HL / NHLBI NIH HHS / United States U01 HL123031 / HL / NHLBI NIH HHS / United States |